GlobalData on MSN21h
Novo Nordisk plans new study for CagriSema, targets 2026 submission
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
BioSpace4h
After Unforced Error, Novo Execs Try to Boost CagriSema Sentiment—Without Hard Numbers
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...
Trump's Greenland dreams could ding huge North Carolina employer
Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...
Super Bowl Ad Raises Questions About Compounded Versus Branded Obesity Meds
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...
Hosted on MSN6h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Investor's Business Daily on MSN46m
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
Hims stock surged above a profit-taking zone Friday after facing backlash over its provocative Super Bowl ad that criticized the makers of approved weight-loss drugs. Please watch the video at ...
STAT4h
Lilly expands GLP-1 research to hypertension, neuro conditions
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...
World Trademark Review23h
How Novo Nordisk and Eli Lilly file for their well-known weight-loss brands
Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...